Oncology Drugs Companies

Bristol Myers Squibb acquired Mirati Therapeutics in October 2023  deal strengthens Bristol Myers Squibb's presence in lung cancer treatment, particularly with Mirati's promising KRAS G12C inhibitor adagrasib.

AbbVie acquired ImmunoGen in November 2023 expands AbbVie's portfolio of antibody-drug conjugates (ADCs) with the addition of ELAHERE for platinum-resistant ovarian cancer.

SpringWorks Therapeutics received FDA breakthrough therapy designation for nirogacestat in desmoid tumors in November 2023 could expedite the drug's approval process for this rare cancer.

AstraZeneca's Lynparza received expanded FDA approval for ovarian cancer maintenance treatment in October 2023 extends its reach in the market and offers a PARP inhibitor option for a wider range of patients.

Roche presented positive Phase 3 data for atezolizumab in early-stage non-small cell lung cancer (NSCLC) at the ESMO Congress in December 2023 results could lead to atezolizumab becoming a standard first-line treatment for early-stage NSCLC.

List of Oncology drugs Key Companies in the Market

• Hoffmann-La Roche Ltd.


• Genentech, Inc.


• Novartis AG


• Pfizer Inc.


• Bristol Myers Squibb Company


• GlaxoSmithKline plc


• Eli Lilly and Company


• AstraZeneca


• Sanofi


• Bayer AG


• Merck & Co., Inc.